Chapter 12. Alphastatin: a Pluripotent Inhibitor of Activated Endothelial Cells

  1. Dietmar W. Siemann3,4
  1. Carolyn A. Staton1 and
  2. Claire E. Lewis2

Published Online: 31 MAY 2006

DOI: 10.1002/0470035439.ch12

Vascular-Targeted Therapies in Oncology

Vascular-Targeted Therapies in Oncology

How to Cite

Staton, C. A. and Lewis, C. E. (2006) Alphastatin: a Pluripotent Inhibitor of Activated Endothelial Cells, in Vascular-Targeted Therapies in Oncology (ed D. W. Siemann), John Wiley & Sons, Ltd, Chichester, UK. doi: 10.1002/0470035439.ch12

Editor Information

  1. 3

    Shands Cancer Center, University of Florida, Gainsville, Florida, USA

  2. 4

    Research Department of Radiation Oncology, University of Florida, 2000 RW Archer Road, Gainsville, FL 32610, USA

Author Information

  1. 1

    Academic Unit of Surgical Oncology, Division of Clinical Sciences (South), K Floor, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK

  2. 2

    Section of Oncology and Pathology, Division of Genomic Medicine, University of Sheffield Medical School, Beech Hill Road, Sheffield S10 2RX, UK

Publication History

  1. Published Online: 31 MAY 2006
  2. Published Print: 10 MAR 2006

ISBN Information

Print ISBN: 9780470012949

Online ISBN: 9780470035436



  • alphastatin activity in vivo;
  • pluripotent inhibitor of activated endothelial cells;
  • anti-angiogenic therapy;
  • fibrinogen E-fragment;
  • fibrinogen alpha chain structure;
  • alphastatin structure;
  • inhibiting endothelial migration and tubule formation in vitro


This chapter contains sections titled:

  • Introduction

  • Discovery of alphastatin

  • Development of alphastatin

  • Conclusions

  • References